Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma

Clinical Cancer Research

Volumn 10, Issue 18 II, 2004, Pages

  Atkins, Michael B ^a,c   Regan, Meredith ^b,c   McDermott, David ^a,c   Yang, James ^d   Bukowski, Ronald ^d   Linehan, W Marston ^d   Lipton, Allan ^d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c DANA FARBER HARVARD CANCER CENTER   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BEVACIZUMAB; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; ISOTRETINOIN; MEDROXYPROGESTERONE; MOLECULAR MARKER; RECOMBINANT INTERLEUKIN 12; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; VINBLASTINE;

ACUTE RESPIRATORY TRACT DISEASE; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CHILL; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DOSE RESPONSE; DRUG ACTIVITY; DRUG APPROVAL; DRUG COST; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; FATIGUE; FEVER; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY CARCINOMA; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LOW DRUG DOSE; MYALGIA; NEPHRECTOMY; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY DISTRESS SYNDROME; TASTE DISORDER; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR REGRESSION; WEIGHT REDUCTION;

CARCINOMA, RENAL CELL; CYTOKINES; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOPLASM STAGING;

EID: 4644335916     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-040029     Document Type: Conference Paper

References (35)

1. Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 1998;338:1265-71.
2. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol 1992;148:1247-8.
3. McDermott DF, Atkins MB. Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther. 2004;4:455-68.
4. Marten A, Flieger D, Renoth S, et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 2002;51:637-44.
5. Fishman M, Seigne J. Immunotherapy of metastatic renal cell cancer. Cancer Control 2002;9:293-304.
6. Gitlitz BJ, Belldegrun AS, Figlin RA. Vaccine and gene therapy of renal cell carcinoma. Semin Urol Oncol 2001;19:141-7.
7. Muss HB. Interferon therapy for renal cell carcinoma. Semin Oncol 1987;14:36-42.
8. Neidhart JA. Interferon therapy for the treatment of renal cancer. Cancer 1986;57:1696-9.
9. Muss HB, Costanzi JJ, Leavitt R, et al. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol 1987;5:286-91.
10. Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, Rintala E, Hietanen P, Kellokumpu-Lehtinen PL. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17:2859-67.
11. Collaborators MRC. a. Interferon alfa and survival in metastatic renal carcinoma: Early results of a randomized controlled trial. Lancet 1999;353:14-7.
12. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18:2972-80.
13. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96.
14. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6 Suppl 1:S55-7.
15. Dutcher JP, Atkins MB, Fisher R, et al. Interleukin-2 based therapy for metastatic renal cell cancer: The Cytokine Working Group Experience. Can J Sci Am 1997;3:S73-8.
16. Dutcher JP, Fisher RI, Weiss G, et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997;3:157-62.
17. Dutcher JP, Logan T, Gordon M, et al. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res 2000;6:3442-50.
18. Negrier S, Caty A, Lesimple T, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d'Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2000;18:4009-15.
19. McDermott D, Flaherty L, Clark J, et al. A randomized phase III trial of high-dose interleukin-2 (HD IL2) versus subcutaneous (SC) lL2/interferon (IFN) in patients with metastatic renal cell carcinoma (RCC). A Cytokine Working Group Study. Proc Am Soc Clin Oncol 2001;2072a.
20. Atkins MB, McDermott DF. Results of the Cytokine Working Group phase III trial of high dose IL-2 vs. low dose IL-2 and IFN therapy in patients with metastatic renal cell carcinoma. Cancer Invest 2003 Suppl 1 21:S87-8.
21. McDermott D, Parker R, Youmans A, Connolly C, Atkins M. The effect of recent nephrectomy on treatment with high-dose interleukin-2 (HD IL-2) or subcutaneous (SC) IL-2/interferon alfa-2b (IFN) in patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2003;22:385A.
22. Cole B, McDermott D, Parker R, Youmans A, Connolly C, Ernstoff M, Atkins M. The impact of treatment with high-dose interleukin-2 (HD IL-2) or subcutaneous (SC) IL-2/interferon alfa-2b (IFN) on quality of life (QOL) in patients with metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol 2003;22:387A.
23. Yang JC, Sherry RM, Steinberg SM, et al. A three-arm randomized comparison of high and low dose intravenous and subcutaneous interleukin-2 in the treatment of metastatic renal cancer. J Clin Oncol 2003;21:3127-32.
24. Margolin K, Aronson FR, Sznol M, Atkins MB, Dutcher J, Fisher RI, Weiss GR, Stewart M, Doroshow JH. Phase II evaluation of thrice-daily intravenous bolus interleukin-4 in advanced renal cell and malignant melanoma. J Immunother 1994;15:147.
25. Weiss GR, Margolin KA, Sznol M, et al. A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma. J Immunother Emphasis Tumor Immunol 1995;18:52-6.
26. Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin-12 (RHIL-12) in patients with advanced malignancies. Clin Cancer Res 1997;3:409-17.
27. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997;90:2541-8.
28. Gollob JA, Mier JW, Veenstra K, et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000;6:1678-92.
29. Gollob JA, Veenstra KG, Parker RA, et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 2003;21:2564-73.
30. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96.
31. Figlin R, Gitlitz B, Franklin J, et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am 1997;3 Suppl 1:S92-7.
32. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;98:2566-75.
33. Upton MP, Parker RA, Youmans A, Connolly C, Atkins MB. Histologic predictors of renal cell carcinoma (RCC) response to interleukin-2 based therapy. Proc Am Soc Clin Oncol 2003;22:851A.
34. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003;9:802-11.
35. Atkins M, McDermott D, Mier J, et al. Carbonic anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy. Proc Am Soc Clin Oncol 2004;23:383A.